Stocks · Health care · Pharmaceutical Preparations

CervoMed Inc.

CRVO Clue Score35
United States Fiscal year ends December CIK 0001053691
$3.22 -1.83% Close, 9 Oct 2026
Price $3.22 +594.26% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 12 Oct 2016. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2016Operating income−18.4Net income−18.0EPS, diluted−1.76Fiscal year 2017Operating income−11.3Net income−1.4EPS, diluted−29.11Fiscal year 2018Operating income−19.0Net income−18.4EPS, diluted3,242,301.00Fiscal year 2019Operating income−11.6Net income−11.8EPS, diluted6,706,509.00Fiscal year 2020Operating income−16.0Net income−14.2EPS, diluted53,831,973.00Fiscal year 2021Operating income−24.7Net income−24.1EPS, diluted1,946,859.00Fiscal year 2022Revenue0.0Operating income−3.5Net income−5.8EPS, diluted2,038,891.00Fiscal year 2023Revenue7.1Operating income−7.8Net income−2.2Fiscal year 2024Revenue9.7 +36.3%Operating income−18.2Net income−16.3Fiscal year 2025Revenue4.0 −58.9%Operating income−28.3Net income−27.0
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue n/a n/a n/a n/a n/a n/a 0.0 7.1 9.7 4.0
Growth +36.3% −58.9%
Operating income −18.4 −11.3 −19.0 −11.6 −16.0 −24.7 −3.5 −7.8 −18.2 −28.3
Net income −18.0 −1.4 −18.4 −11.8 −14.2 −24.1 −5.8 −2.2 −16.3 −27.0
Growth
EPS, diluted −1.76 −29.11 3,242,301.00 6,706,509.00 53,831,973.00 1,946,859.00 2,038,891.00 n/a n/a n/a

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2016Fiscal year 2017Fiscal year 2018Fiscal year 2019Fiscal year 2020Fiscal year 2021Fiscal year 2022Fiscal year 2023Operating margin−109.3%Net margin−30.4%Fiscal year 2024Operating margin−187.2%Net margin−167.3%Fiscal year 2025Operating margin−706.2%Net margin−673.1%
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating margin n/a n/a n/a n/a n/a n/a n/a −109.3% −187.2% −706.2%
Net margin n/a n/a n/a n/a n/a n/a n/a −30.4% −167.3% −673.1%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2016Operating cash flow−10.8Capital expenditure−0.0Free cash flow−10.8Fiscal year 2017Operating cash flow−12.3Capital expenditure−0.4Free cash flow−12.8Fiscal year 2018Operating cash flow−10.8Fiscal year 2019Operating cash flow−9.9Fiscal year 2020Operating cash flow−13.6Fiscal year 2021Operating cash flow−14.5Fiscal year 2022Operating cash flow−2.6Fiscal year 2023Operating cash flow−7.4Fiscal year 2024Operating cash flow−16.5Fiscal year 2025Operating cash flow−23.4
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −10.8 −12.3 −10.8 −9.9 −13.6 −14.5 −2.6 −7.4 −16.5 −23.4
Capital expenditure −0.0 −0.4 n/a n/a n/a n/a n/a n/a n/a n/a
Free cash flow −10.8 −12.8 n/a n/a n/a n/a n/a n/a n/a n/a
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2016Cash1.6Shareholders’ equity9.2Fiscal year 2017Cash8.9Shareholders’ equity21.2Fiscal year 2018Cash8.0Shareholders’ equity15.6Fiscal year 2019Cash14.2Shareholders’ equity20.1Fiscal year 2020Cash18.5Shareholders’ equity24.8Fiscal year 2021Cash37.3Shareholders’ equity34.9Fiscal year 2022Cash4.1Shareholders’ equity−33.3Fiscal year 2023Cash7.8Shareholders’ equity7.4Fiscal year 2024Cash9.0Shareholders’ equity39.2Fiscal year 2025Cash8.2Shareholders’ equity18.2
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash 1.6 8.9 8.0 14.2 18.5 37.3 4.1 7.8 9.0 8.2
Shareholders’ equity 9.2 21.2 15.6 20.1 24.8 34.9 −33.3 7.4 39.2 18.2

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Balance sheet

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2016 31 Dec 2016 FY2017† 31 Dec 2017 FY2018† 31 Dec 2018 FY2019 31 Dec 2019 FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Assets
1.6 8.9 8.0 14.2 18.5 37.3 4.1 7.8 9.0 8.2
0.1 0.5 0.4 0.3 0.1 0.0 n/a n/a n/a n/a
6.9 6.9 0.0 n/a n/a n/a n/a n/a n/a n/a
17.5 26.1 18.2 24.1 27.7 37.8 4.2 10.0 43.1 22.9
Growth +49.5% −30.4% +32.5% +15.0% +36.5% −89.0% +139.9% +332.0% −46.9%
Liabilities
8.3 4.9 2.6 4.0 2.9 2.9 13.2 2.6 3.9 4.7
Equity
−60.2 −61.6 −79.9 −91.7 −105.9 −130.0 −52.3 −54.4 −70.7 −97.7
9.2 21.2 15.6 20.1 24.8 34.9 −33.3 7.4 39.2 18.2
Growth +131.1% −26.5% +29.0% +23.2% +40.7% −195.3% +431.4% −53.5%
Per share and net cash
10.3 1.0 3.4 33.5 64.0 2.0 0.5 5.7 8.7 9.3
calc 0.89 21.93 4.62 0.60 0.39 17.13 −64.24 1.30 4.50 1.97

† The diluted share count jumps at 2017 and 2018, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Lines marked calc are worked out here from filed figures; point at one for how.